IgGenix

[Available On-Demand]
At IgGenix, our mission is to develop a first-in-class therapy for millions of people whose daily lives are limited by food allergies and other severe allergic conditions. With a deep understanding of molecular immunology, we employ an antibody-based therapeutic platform to potentially enable faster, deeper and more sustained clinical responses. We push the limits of single-cell genomic technology to capture and analyze very rare human B cells expressing allergen binding antibodies. We engineer these antibodies to uniquely capture allergens and endow them with powerful immune modulating activities derived from the IgG antibody class to suppress allergic reactions. Our team is at work today to make this new life changing therapy tomorrow’s reality.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Lead Product in Development:
IGGX 1
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
CEO
IgGenix, Inc.